CoChat
Sign Up
Cited by 55Gastrointestinal motility and disordersInfant Health and DevelopmentPelvic floor disorders treatments

Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome

Open access
Thumshirn, Coulie, Camilleri, Zinsmeister, Burton, Van Dyke·2000·Alimentary Pharmacology & Therapeutics
DOI 10.1046/j.1365-2036.2000.00786.x
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Alosetron, a 5-HT3-receptor antagonist, relieves abdominal pain and improves bowel function in non-constipated, female patients with irritable bowel syndrome. 5-HT3 antagonists delay colonic transit, increase colonic compliance, and increase small intestinal water absorption. AIM: To evaluate the effects of alosetron on gastrointestinal and colonic transit, rectal compliance and rectal sensation in irritable bowel syndrome. METHODS: A double-blind, placebo-controlled, two-dose study of alosetron was performed in 25 non-constipated irritable bowel syndrome patients, with paired studies before and after 4 weeks of treatment with placebo (n=5), 1 mg alosetron (n=10) or 4 mg (n=10) alosetron b.d. Gastrointestinal and colonic transit were measured by scintigraphy. Rectal compliance and sensation were assessed by rectal balloon distention with a barostat. RESULTS: There was a trend (P=0.06) for 1 mg alosetron to increase rectal compliance (median pressure at half maximum volume 11 mmHg after alosetron vs. 15.6 mmHg before alosetron). The 1 mg b.d. alosetron dose non-significantly retarded proximal colonic transit. Alosetron and placebo reduced sensory scores relative to baseline values; none of the changes induced by alosetron was significant relative to placebo. CONCLUSIONS: Alosetron had no significant effect on gastrointestinal transit or rectal sensory and motor mechanisms in non-constipated irritable bowel syndrome patients in this study. Alosetron's effects on colonic sensorimotor function and central sensory mechanisms deserve further evaluation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2000.00786.x

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • 5-HT3 antagonists alter rectal compliance.

    “5-HT3 antagonists also alter rectal compliance”

    From Irritable bowel syndrome (2020) · cites this paper as [120]

    The Introduction reports that the 5-HT3 antagonist ondansetron increased rectal compliance in patients with irritable bowel syndrome. But the paper's own 'Effect of alosetron on rectal compliance' section found no statistically significant effect for the tested doses of alosetron, so it does not support the unqualified statement about 5-HT3 antagonists generally. Page numbers were not supplied. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 47 · Cited by 55

Research works printed but not linked: 47

  1. Drossman DA, Camilleri M, Whitehead WE. Irritable bowel syndrome: a technical review for practice guideline develop- ment. Gastroenterology 1997; 112: 2120±37.
  2. Camilleri M, Choi M-G. Review article: Irritable bowel syn- drome. Aliment Pharm Ther 1997; 11: 3±15.
  3. Everhart JE, Renault PF. Irritable bowel syndrome in of®ce- based practice in the United States. Gastroenterology 1991; 100: 998±1005.
  4. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282±4.
  5. Evans PR, Bennett EJ, Bak YT, Tennant CC, Kellow JE. Jejunal sensorimotor dysfunction in irritable bowel syndrome: clinical and psychological features. Gastroenterology 1996; 110: 393±404.
  6. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance of rec- tosigmoid distention in irritable bowel syndrome. Gas- troenterology 1990; 98: 1187±92.
  7. Munakata J, Naliboff B, Harraf F, et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irri- table bowel syndrome. Gastroenterology 1997; 112: 55±63.
  8. Ritchie J. Pain from distension of the pelvic colon by in¯ating a balloon in the irritable bowel syndrome. Gut 1973; 14: 123±32.
  9. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irri- table bowel syndrome. Gastroenterology 1995; 109: 40±52.
  10. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon in¯uences stool weight in the irritable bowel syndrome. Gastroenterology 1992; 102: 102±8.
  11. Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983; 24: 405±11.
  12. Moss HE, Sanger GJ. The effects of granisetron, ICS 205±930 and ondansetron on the visceral pain re¯ex induced by duo- denal distention. Br J Pharm 1990; 100: 497±501.
  13. Scott CM, Grundy D, Boissonade F, Bountra C. Alosetron inhibits the colorectal distention-evoked depressor response and spinal c-fos expression in the anesthetized rat. Gast- roenterology 1997; 112: A822(Abstract).
  14. Talley NJ. 5-Hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1990; 25: 273±89.
  15. Prior A, Read NW. Reduction of rectal sensitivity and post- prandial motility by granisetron, a 5HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharm Ther 1993; 7: 175±80.
  16. Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distention and serotonin type 3 antagonism. Dig Dis Sci 1995; 40: 819±27.
  17. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxy- tryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharm Ther 1996; 10: 595±9.
  18. Steadman CJ, Talley NJ, Phillips SF, et al. Selective 5-hy- droxytryptamine type 3 receptor antagonism with ondanse- tron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992; 67: 732±8.
  19. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JRM, Roth C. Modi®cation of visceral sensitivity and pain in irritable bowel syndrome by 5HT3 antagonism (ondansetron). Diges- tion 1996; 57: 748±83.
  20. Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydrxytryptamine receptor (type 3) antagonist. Aliment Pharm Ther 1990; 4: 139±44.
  21. Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35: 477±80.
  22. von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut 1994; 35: 536±41.
  23. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5HT 3 -receptor antagonist. Aliment Phar- macol Ther 1999; 13: 1149±59.
  24. Forster JM, Houghton LA, Whorwell PJ. Alosetron slows colonic transit in patients with irritable bowel syndrome. Gastroenterology 1997; 112: A732(Abstract).
  25. Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol J-L, Frex- inos J. The agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999; 116: 38±45.
  26. Manning AP, Thompson WD, Heaton KW, Morris AF. Towards a positive diagnosis of the irritable bowel syndrome. Br Med J 1978; 2: 653±4.
  27. Camilleri M, Colemont LJ, Phillips SF, et al. Human gastric emptying and colonic ®lling of solids characterized by a new method. Am J Physiol 1989; 257: G284±90.
  28. Proano M, Camilleri M, Phillips SF, et al. Transit of solids through the human colon: regional quanti®cation in the unprepared bowel. Am J Physiol 1990; 258: G856±62.
  29. Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Pro- ano M. Towards a less costly but accurate test of gastric emp- tying and small bowel transit. Dig Dis Sci 1991; 36: 606±15.
  30. Camilleri M, Zinsmeister AR. Towards a relatively inexpen- sive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992; 103: 36±42.
  31. Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986; 91: 94±9.
  32. Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal com- pared with ion exchange pellets. J Nucl Med 1997; 38: 1807±10.
  33. Azpiroz F, Malagelada JR. Physiological variations in canine gastric tone measured by an electronic barostat. Am J Physiol 1985; 248: G229±37.
  34. Moreels TG, Foley M, Phillips SF. In vitro comparison of internal compliances of three barostats. Dig Dis Sci 1996; 41: A15(Abstract).
  35. Malcolm A, Phillips SF, Camilleri M, Hanson RB. Pharmaco- logical modulation of rectal tone alters perception of distention in humans. Am J Gastroenterol 1997; 92: 2073±9.
  36. Bharucha AE, Camilleri M, Ford MJ, O'Connor MK, Hanson RB, Thomforde GM. Hyperventilation alters colonic motor and sensory function; effects and mechanisms in humans. Gas- troenterology 1996; 111: 368±77.
  37. Ford MJ, Camilleri M, Zinsmeister AR, Hanson RB. Psycho- sensory modulation of colonic sensation in the human transverse and sigmoid colon. Gastroenterology 1995; 109: 1772±80.
  38. Ford MJ, Camilleri M, Joyner MJ, Hanson RB. Autonomic control of colonic tone and the cold pressor test. Gut 1996; 39: 125±9.
  39. Akkervall S, Fasth S, Nordgren S, et al. Manovolumetry: a new method for investigation of anorectal function. Gut 1988; 29: 614±23.
  40. Bell AM, Pemberton JH, Hanson RB, et al. Variations in muscle tone of the human rectum: recordings with an elec- tromechanical barostat. Am J Physiol 1991; 260: G17±25.
  41. Hammer HF, Phillips SF, Camilleri M, Hanson RB. Rectal tone, distensibility, and perception: reproducibility and response to different distentions. Am J Physiol 1998; 274: G584±90.
  42. Saslow SB, Scolapio JS, Camilleri M, et al. Medium term effects of a new 5HT3 antagonist, alosetron, in patients with carci- noid diarrhea. Gut 1998; 42: 628±34.
  43. Zerbib F, Bruley des Varannes S, Oriola RC, McDonald J, Isal JP, Galmiche JP. Alosetron does not affect the visceral per- ception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8: 403±7.
  44. Bearcroft CP, Andre EA, Farthing MJ. In vivo effects of the 5±HT3 antagonist alosetron on basal and cholera toxin- induced secretion in the human jejunum: a segmental perfusion study. Aliment Pharmacol Ther 1997; 11: 1109±14.
  45. Greenshaw AJ, Silverstone PH. The non-antiemetic uses of serotonin 5HT3 receptor antagonists. Drugs 1997; 53: 20±39.
  46. Miura M, Lawson C, Clary EM, Mangel AW, Pappas TN. Central modulation of rectal distension-induced blood pres- sure changes by alosetron, a 5-HT3 receptor antagonist. Dig Dis Sci 1999; 44: 20±4.
  47. Nishizawa S, Benkelfat C, Young SN, et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA 1997; 94: 5308±13.

Authors
Thumshirn, Coulie, Camilleri, Zinsmeister, Burton, & Dyke, V.
Affiliations
Mayo Clinic (US)
Corresponding author
Camilleri
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2000-07
Volume
14
Issue
7
Pages
869-878
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
DOI
10.1046/j.1365-2036.2000.00786.x
OpenAlex
W2075855583
Cited by
55
References
47
Citations by year
2024: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2015: 1 · 2014: 1 · 2012: 3
FWCI
6.42
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 541 d)
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (and K24, NIH-R01)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K24 DK02638, R01 DK-54681, K24DK002638, R01DK054681)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Health Professions › Pharmacy › Infant Health and Development
  • Health Sciences › Medicine › Rheumatology › Pelvic floor disorders treatments
Keywords
alosetron, irritable bowel syndrome, 5-HT3 receptor antagonists, colonic transit, gastrointestinal transit, rectal compliance, rectal sensation, scintigraphy
MeSH terms
Adult, Aged, Carbolines, Colonic Diseases, Functional, Double-Blind Method, Female, Gastrointestinal Transit, Humans, Male, Middle Aged, Psychomotor Performance, Rectum, Serotonin Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review